Results 41 to 50 of about 3,063 (143)

Efficacy and Safety of Baricitinib in Chinese Rheumatoid Arthritis Patients and the Subgroup Analyses: Results from Study RA-BALANCE

Rheumatology and Therapy, 2020
Introduction Baricitinib is an oral selective inhibitor of Janus kinase (JAK) 1 and JAK 2, which has demonstrated significant efficacy in patients with moderately to severely active rheumatoid arthritis (RA).
Yue Yang, Xing-Fu Li, Xiao Zhang, Chun-De Bao, Jian-Kang Hu, Jian-Hua Xu, Xiang-Pei Li, Jian Xu, Dong-Yi He, Zhi-Jun Li, Guo-Chun Wang, Han-Jun Wu, Fei Ji, Lu-Jing Zhan, Cristiano A. F. Zerbini, Zhan-Guo Li   +15 more
doaj   +1 more source

Baricitinib: A Review in Severe Alopecia Areata

, 2023
Declarations Funding The preparation of this review was not supported by any external funding. Authorship and Conflict of interest S. Fung and M. Shirley are salaried employees of Adis International Ltd/Springer Nature, and declare no relevant conflicts ...
Matt Shirley (7340599), Simon Fung (14588847)   +1 more
core   +1 more source

Baricitinib in rheumatoid arthritis – real world cross-sectional study [PDF]

, 2020
© 2020 The Authors. Published by Bentham Open. This is an open access article available under a Creative Commons licence. The published version can be accessed at the following link on the publisher’s website: 10.2174/1874312902014010028Introduction ...
Morrissey, Hana, Askari, Ayman, Ball, Patrick, Sagdeo, Amol   +3 more
core   +1 more source

Characterization and changes of lymphocyte subsets in baricitinib-treated patients with rheumatoid arthritis: an integrated analysis [PDF]

, 2018
Objective: Baricitinib is an oral selective inhibitor of Janus kinase (JAK) 1 and JAK2 that is efficacious in patients with rheumatoid arthritis (RA).
Tanaka, Y, Nicole L. Byers, Issa, Maher, William L. Macias, Byers, Nicole L, Schlichting, Douglas E., Tanaka, Yoshiya, de Bono, S, Chen, L, Stephanie de Bono, Macias, William L, Schlichting, Douglas E, Rooney, Terence P., Douglas E. Schlichting, Zuckerman, Steven H, McInnes, Iain B., de Bono, Stephanie, Byers, NL, Terence P. Rooney, Peter C. Taylor, Macias, WM, Lei Chen, Byers, Nicole L., Yoshiya Tanaka, Macias, WL, Issa, M, Steven H. Zuckerman, Chen, Lei, Zuckerman, SH, Paul Emery, McInnes, IB, Veronica Rogai, Rogai, Veronica, Zuckerman, Steven H., Rogai, V, Taylor, PC, McInnes, Iain B, Maher Issa, Taylor, Peter C, Emery, P, Taylor, Peter C., Macias, William L., Rooney, TP, Schlichting, DE, Iain B. McInnes, Rooney, Terence P, Emery, Paul   +46 more
core   +1 more source

Efficacy of baricitinib in severe coronavirus disease 2019

, 2023
Background Coronavirus disease 2019 (COVID-19) binds to angiotensin-converting enzyme through a viral spike protein prompting an inflammatory cascade. Baricitinib, an oral drug, is a selective inhibitor of Janus kinase (JAK) 1 and 2 and interferes with ...
Doaa B Mousa, Azza A Ahmed, Ahmed M A E F Amer   +2 more
core   +1 more source

Baricitinib treatment for hospitalized patients with severe COVID-19 on invasive mechanical ventilation: a propensity score-matched and retrospective analysis

Frontiers in Medicine
IntroductionBaricitinib is a selective inhibitor of Janus kinase (JAK)1 and JAK2, which is associated with clinical improvement in non-severe COVID-19 patients.
Yanxiong Mao, Anyi Guo, Ying Zhang, Jianxing Lai, Dian Yuan, Hao Zhang, Wenqi Diao, Weisong Chen, Fugui Yan   +8 more
doaj   +1 more source

Crosstalk between the JAK2 and TGF-β1 signaling pathways in scleroderma-related interstitial lung disease targeted by baricitinib

Advances in Rheumatology, 2023
Background and objective Systemic sclerosis (SSc) is an immune-mediated rheumatic disease characterized by fibrosis and vascular lesions. Interstitial lung disease is an early complication of SSc and the main cause of death from SSc. Although baricitinib
Dandan Wang, Yimei Wei, Lulu Xu, Jie Zhang   +3 more
doaj   +1 more source

Baricitinib ameliorates inflammatory and neuropathic pain in collagen antibody-induced arthritis mice by modulating the IL-6/JAK/STAT3 pathway and CSF-1 expression in dorsal root ganglion neurons

Arthritis Research & Therapy
Background Janus kinase (JAK) inhibitors, such as baricitinib, are widely used to treat rheumatoid arthritis (RA). Clinical studies show that baricitinib is more effective at reducing pain than other similar drugs.
Kenta Makabe, Hiroyuki Okada, Naohiro Tachibana, Hisatoshi Ishikura, Norihito Ito, Masaru Tanaka, Ryota Chijimatsu, Asuka Terashima, Fumiko Yano, Meiko Asaka, Dai Yanagihara, Shuji Taketomi, Takumi Matsumoto, Sakae Tanaka, Yasunori Omata, Taku Saito   +15 more
doaj   +1 more source

Real‐World Safety and Effectiveness of JAK Inhibitors in Systemic Sclerosis: A Propensity‐Matched Study From the EUSTAR Cohort

Arthritis Care &Research, EarlyView.
Objective JAK inhibitors (JAKi) have shown promising effects in early‐phase studies of systemic sclerosis (SSc). We aimed to assess the safety and explore the effectiveness of JAKi compared to conventional immunosuppressants in SSc. Methods A longitudinal retrospective study of the European Scleroderma Trials and Research Group (EUSTAR) cohort was ...
Stefano Di Donato, Marie‐Elise Truchetet, Marco Minerba, Oliver Distler, Juan José Alegre Sancho, Yolanda Braun‐Moscovici, Christina Bergmann, Petros Sfikakis, Jeska K. de Vries‐Bouwstra, Murray Baron, Silvia Bellando‐Randone, Lorenzo Dagna, Christopher P. Denton, Madelon C. Vonk, Vanessa Smith, Ivan Castellvi, Gabriela Riemekasten, Andra Balanescu, Masataka Kuwana, Maria De Santis, Kamal Solanki, Anastas Batalov, Vahan Mukuchyan, Marco Matucci‐Cerinic, Yannick Allanore, Francesco Del Galdo, Michael Hughes, EUSTAR Collaborators   +27 more
wiley   +1 more source

Baricitinib in therapy of COPA syndrome in a 15-year-old girl

, 2019
COPA syndrome is a newly discovered hereditary immunodeficiency affecting the lung, kidneys, and joints. The mutated gene encodes the α subunit of the coatomer complex I, a protein transporter from the Golgi back to the endoplasmic reticulum.
Horneff, Gerd, Krutzke, Sophia, Sophia Krutzke, Rietschel, Christoph, Christoph Rietschel, Gerd Horneff   +5 more
core   +1 more source